Science
Lanova Medicines Announces Initiation Of Phase 1 Clinical Trial Of Anti-PD-1/VEGF Bispecific Antibody LM-299 And Completion Of $42 Million Series C1 Financing
(MENAFN - PR Newswire) Phase 1 trial of LM-299, an anti-PD-1/VEGF BsAb, initiated in China for advanced solid tumors following promising preclinical results demonstrating strong inhibition ...
By: menafn
- Oct 18 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS